Vasopressin in vasoplegic shock: A systematic review

Table 4 Trial outcomes

Comparison	Vasopressin vs norepinephrine		Vasopressin vs methylene blue
Study	Hajjar et al[24], 2017	Cheng et al[23], 2018	El Adawy et al[25], 2016
Study design	Randomized trial	Cohort	Randomized trial
Sample size	330	338	40
30-d mortality	RR 0.97, 95%CI 0.57, 1.64; moderate	RR 3.33, 95%CI 0.93, 11.90; very low	-
Ventricular arrhythmia	RR 0.86, 95%CI 0.54, 1.35; moderate	RR 1.75, 95%CI 1.11, 2.76; very low	-
Duration of vasopressors	MD -23.00 d, 95%CI -36.12, -9.88; moderate	MD 24 d, 95%CI 16.32, 31.68; very low	-
Intensive care unit length of stay	MD -1.00 d, 95%CI -1.69, -0.31; moderate	MD 1.00 d, 95%CI 0.53, 1.47; low	MD 1.60 d, 95%CI -0.29, 3.49; very low
Stroke	RR 1.01, 95%CI 0.26, 3.98; low	RR 0.50, 95%CI 0.13, 1.97; very low	-
Acute kidney injury stage II/III	RR 0.32, 95%CI 0.21, 0.49; moderate	RR 1.12, 95%CI 0.89, 1.42; very low	-
Atrial arrhythmia	RR 0.78, 95%CI 0.67, 0.89; moderate	RR 1.70, 95%CI 1.02, 2.83; low	-
Mechanical ventilation > 48 h	RR 0.62, 95%CI 0.27, 1.46; low	RR 0.95, 95%CI 0.63, 1.42; very low	-

Data is presented as effect size, 95% confidence interval (CI), certainty of evidence. CI: Confidence interval; MD: Mean difference; RR: Relative risk.